Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML16 trial in acute myeloid leukemia and high-risk myelodysplastic syndromes
2005-002847-14Phase 2Completed
- Sponsor
- Cardiff University
- Start
- Aug 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of clofarabine, gemtuzumab ozogamicin, azacitidine and tipifarnib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Cardiff University. Primary endpoint: Prognostic impact of cytogenetic abnormalities in remission. Started Aug 2005; status: completed.
02
Drugs
clofarabinegemtuzumab ozogamicinazacitidinetipifarnib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-002847-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002847-14.